Patents Examined by Brian E McDowell
-
Patent number: 11655218Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?). A form-II crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?).Type: GrantFiled: December 28, 2020Date of Patent: May 23, 2023Assignee: NIPPON SHINYAKU CO., LTD.Inventor: Toshio Fujiwara
-
Patent number: 11655239Abstract: The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof.Type: GrantFiled: July 17, 2020Date of Patent: May 23, 2023Assignee: Shanghai Institute Of Material Medica, Chinese Academy of SciencesInventors: Bing Xiong, Jia Li, Meiyu Geng, Jingkang Shen, Yi Zang, Jing Ai, Danqi Chen, Qi Wang, Ying Dong, Xia Peng, Yinchun Ji, Qian Tan
-
Patent number: 11653558Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is selected from is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, RE, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.Type: GrantFiled: May 22, 2019Date of Patent: May 16, 2023Assignee: Universal Display CorporationInventors: Bin Ma, Edward Barron, Alan DeAngelis, Walter Yeager, Zeinab Elshenawy, Harvey Wendt, Ting-Chih Wang, Kwang-Ohk Cheon, Chuanjun Xia
-
Patent number: 11639342Abstract: Compositions, methods, and kits for the labeling, detecting, isolating and/or analysis of biomolecules modified by attachment of chemical handles are disclosed.Type: GrantFiled: January 10, 2020Date of Patent: May 2, 2023Assignee: BIOCONJUGATE TECHNOLOGIES, LLCInventors: Andrei Polukhtin, Peter J. An, Alexandra Kulyashova, Jakub M. Labedz, Valentin A. Rassadin, Nikita V. Savelyev, Kostiantyn Ziabrev
-
Patent number: 11639350Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject, and the compound has the structure of Formula I including any possible deuterated isomers, stereoisomers or tautomeric forms thereof.Type: GrantFiled: June 26, 2018Date of Patent: May 2, 2023Assignee: Janssen Pharmaceutica NVInventors: Zhao-Kui Wan, Yimin Jiang, Xuedong Dai, Qian Liu, Wing Shun Cheung, Gang Deng, Liqiang Fu
-
Patent number: 11634405Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.Type: GrantFiled: April 26, 2019Date of Patent: April 25, 2023Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
-
Patent number: 11634406Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.Type: GrantFiled: September 24, 2020Date of Patent: April 25, 2023Assignee: RESPIVERT LTD.Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
-
Patent number: 11631825Abstract: An iridium complex which has a phenylpyridine bidentate ligand containing a group represented by the following general formula (A): wherein X represents a cyano group or a halogenated alkyl group; L represents a single bond or a divalent linking group; R represents a substituent; n represents an integer of 0 to 4; * represents a binding site to a phenylpyridine bidentate ligand.Type: GrantFiled: November 6, 2020Date of Patent: April 18, 2023Assignee: UDC IRELAND LIMITEDInventors: Kousuke Watanabe, Yuichirou Itai
-
Patent number: 11623923Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.Type: GrantFiled: November 23, 2018Date of Patent: April 11, 2023Assignee: MEDSHINE DISCOVERY, INC.Inventors: Jinping Li, Xiongbin Xu, Gang Li, Lihong Hu, Charles Z. Ding, Yaling Zhou, Guoping Hu, Jian Li, Shuhui Chen
-
Patent number: 11613527Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: GrantFiled: October 8, 2021Date of Patent: March 28, 2023Assignee: KalVista Pharmaceuticals LimitedInventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
-
Patent number: 11608337Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.Type: GrantFiled: September 25, 2020Date of Patent: March 21, 2023Assignee: Incyte CorporationInventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
-
Patent number: 11597723Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.Type: GrantFiled: March 14, 2018Date of Patent: March 7, 2023Assignees: Fondazione Istituto Italiano Di Technologia, Istituto Giannina Gasiini, FondaZione Per La Ricerca Sulla Fibrosi Cristica—OnlusInventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
-
Patent number: 11591342Abstract: Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).Type: GrantFiled: February 14, 2019Date of Patent: February 28, 2023Assignee: SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.Inventors: Yonghan Hu, Dongdong Wu, Wei Peng, Xin Li, Fan Hu, Bin Huang, Jinlian Zhu, Yuchuan Wu
-
Patent number: 11591317Abstract: The invention relates to an organic molecule, in particular for use in organic optoelectronic devices. According to the invention, the organic molecule has a structure of Formula I wherein Q is at each occurrence N or CRIII; W is at each occurrence N or CRIV; Z is at selected from the group consisting of a direct bond, CR3R4, C?CR3R4, C?O, C?NR3, NR3, O, SiR3R4, S, S(O) and S(O)2; RA is selected from the group consisting of CN and CF3; and wherein exactly one Q and exactly one W is N.Type: GrantFiled: October 1, 2018Date of Patent: February 28, 2023Assignee: Samsung Display Co., Ltd.Inventor: Alhama Arjona Esteban
-
Patent number: 11590233Abstract: A porphyrin compound of Formula III and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.Type: GrantFiled: December 17, 2018Date of Patent: February 28, 2023Assignee: ONCOSELECT THERAPEUTICS, LLCInventors: Maria Zannes, Vivienne I. Rebel, William E. Bauta
-
Patent number: 11591338Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.Type: GrantFiled: October 19, 2020Date of Patent: February 28, 2023Assignee: Incyte CorporationInventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
-
Patent number: 11591353Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.Type: GrantFiled: June 6, 2022Date of Patent: February 28, 2023Assignee: Mindset Pharma Inc.Inventors: Abdelmalik Slassi, Joseph Araujo
-
Patent number: 11584737Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: March 28, 2019Date of Patent: February 21, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
-
Patent number: 11578042Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.Type: GrantFiled: August 11, 2020Date of Patent: February 14, 2023Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 11578074Abstract: A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target.Type: GrantFiled: August 31, 2018Date of Patent: February 14, 2023Assignee: Shanghai Pharmaceuticals Holding Cd., Ltd.Inventors: Guangxin Xia, Di Li, Jing Zhang, Lingjun Duan, Hongjian Zuo, Wenbo Xiao, Jia Xu, Yanjun Liu